secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106227
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Q2 net loss $76.6M; cash ~$1B; KT-621 Phase 1 data positive; Gilead CDK2 deal up to $750M
--------------------------------------------------------------------------------

- Net loss widened to $76.6M in Q2 2025 ($42.1M Q2 2024); R&D spend rose to $78.4M from $59.2M.
- Cash ~$1B as of July 31, 2025 (including $250M equity offering and Gilead upfront); runway into H2 2028.
- KT-621 Phase 1 healthy volunteer: deep STAT6 degradation, safety undifferentiated from placebo; Phase 1b AD data expected 4Q25; Phase 2b AD/asthma start 4Q25/1Q26.
- Gilead partnership for CDK2 molecular glue: up to $750M total payments including up to $85M upfront/option; Kymera leads research.
- Sanofi to advance KT-485 (IRAK4) into Phase 1 in 2026; $20M preclinical milestone achieved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000095017025106227/0000950170-25-106227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000095017025106227/kymr-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer